Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has widened its licensing deals with four Indian drug manufactures - Hetero Drugs, Mylan’s Matrix Laboratories, Ranbaxy Laboratories and Strides Arcolab, to produce and market the generic versions of three of its HIV/AIDS drugs.
Subscribe to our email newsletter
Gilead has also entered into a licensing agreement with the Medicines Patent Pool Foundation.
The agreement allows the Indian firms to market the generic Elvitegravir, Cobicistat and Quad.
Gilead licensed rights to commercialize elvitegravir from Japan Tobacco (JT), and JT is working in close partnership with Gilead to ensure future access to elvitegravir in the developing world.
As per the previous agreements, Gilead licensed Matrix to produce and market active pharmaceutical ingredients and finished products, as well as the generic versions of Viread, Truvada and other TDF-based combinations across 95 developing countries including India to the companies.
Under the current expanded agreement, the Indian drug manufacturers can sell Viread, Truvada and other TDF-based combinations in 16 additional countries.
Additionally they will produce and sell Viread as a treatment for chronic hepatitis B in an expanded territory.
The current expanded deal entitles the Gilead to receive royalty on sales of finished product, and will allow the licensees to sell the product on their own price.
Gilead Corporate and Medical Affairs executive vice president Gregg Alton said their goal is to ensure that as new Gilead HIV therapies are developed and approved, low-cost versions will be rapidly accessible in developing countries without delay.
Mylan president Heather Bresch said they are pleased to expand their collaboration with Gilead as it will enable more individuals living with HIV/AIDS in resource-limited countries to access the newest innovative medicines.